LivaNova vs Merit Medical Systems
LIVN and MMSI side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LIVN and MMSI compare
LivaNova and Merit Medical Systems are about the same size, with market caps of $5.1B and $5.1B.
On earnings, LivaNova is cheaper: it trades at 27.1× trailing earnings, against 31.8× for Merit Medical Systems.
LivaNova grew revenue faster over the last twelve months (12.4% versus 9.1% for Merit Medical Systems).
LivaNova keeps more of each dollar of sales as profit, with a net margin of 12.8% compared with 9.9% at Merit Medical Systems.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LIVN | MMSI |
|---|---|---|
| Size and price | ||
| Market cap | $5.1B | $5.1B |
| Share price | $91.92 | $84.49 |
| Change, 1 year | 66.0% | −0.71% |
| Change, 5 years | 10.3% | 27.8% |
| Beta (5Y) | 0.83 | 0.33 |
| Employees | 3,300 | 7,500 |
| StockData Score | ||
| Total score | 13 | 13 |
| Valuation score | 0 | 4 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 4 (better) | 3 |
| Health score | 5 (better) | 4 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 27.1× (better) | 31.8× |
| P/S | 3.4× | 3.1× (better) |
| P/B | 3.8× | 2.9× (better) |
| EV/EBITDA | 25.8× | 15.5× (better) |
| P/FCF | 34.1× | 24.9× (better) |
| PEG | – | 1.75 |
| FCF yield | 2.9% | 4.0% (better) |
| Fair value | $69.65 | $92.77 |
| Margin of safety | −32.0% | 8.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 12.4% (better) | 9.1% |
| Revenue growth, 5Y average | 8.2% | 9.5% (better) |
| Net income growth (TTM) | – | 35.2% |
| EPS growth (TTM) | – | 36.4% |
| Profitability | ||
| Gross margin | 68.1% (better) | 49.4% |
| Operating margin | 12.7% | 13.5% (better) |
| Net margin | 12.8% (better) | 9.9% |
| FCF margin | 10.1% | 12.6% (better) |
| Return on equity | 15.4% (better) | 9.8% |
| Return on invested capital | 18.2% (better) | 8.5% |
| Financial health | ||
| Debt / equity | 0.22 (better) | 0.42 |
| Net debt / EBITDA | −1.19 | 0.68 (better) |
| Interest coverage | 5.0× | 6.7× (better) |
| Current ratio | 1.45 | 4.52 (better) |
| Altman Z-score | 2.71 | 4.21 (better) |
| Piotroski F-score | 5 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.44% |
| Shareholder yield | 0.00% (better) | −0.44% |
| Ownership | ||
| Held by institutions | 108% | 105% |
| Held by insiders | 0.48% | 2.7% |
| Insider net buying, 12 months | −$1.3M (better) | −$2.7M |
| Short interest, % of float | 11.6% | 6.9% |
Go deeper
- LIVN stock overview
- LIVN income statement
- LIVN valuation and score
- MMSI stock overview
- MMSI income statement
- MMSI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.